Skip to main content

Table 1 Between-group comparisons of baseline demographics, APOE-ε4 carrier status and CSF immune markers

From: Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease

 

ATN groups (n)

Statistical tests

p (p.adj)

CN

A−/T−/N− (173)

A+/T−/N− (62)

A+/T+ or N+ (196)

A−/T+ or N+ (104)

F/χ2/η2/ηp2 (p)

A−/T−/N− vs. A+/T−/N−

A−/T−/N− vs. A+/T+ or N+

A−/T−/N− vs. A−/T+ or N+

A+/T+/N+ vs. A−/T+ or N+

Age mean (SD)

59.65 (8.80)

66.61 (8.12)

68.33 (7.44)

64.94 (9.88)

F = 32.34, η2 = 0.15 (< 0.001)

a< 0.001 (< 0.001)

a< 0.001 (< 0.001)

a< 0.001 (< 0.001)

a< 0.01 (< 0.05)

Female n (%)

95 (54.91)

41 (66.13)

100 (51.02)

56 (53.85)

χ2 = 2.69, (0.452)

c

c

c

c

APOE-ε4+ n (%) [missing n]

59 (33.33) [n = 3]

44 (68.75) [n = 3]

142 (74.35) [n = 7]

39 (38.61) [n = 7]

χ2 = 77.22, (< 0.001)

c

c

c

c

Recruited as controls n (%)

57 (32.95)

9 (14.52)

19 (9.69)

23 (22.12)

 

c

c

c

c

SCD n (%)

116 (67.05)

23 (37.09)

39 (19.90)

29 (27.88)

 

c

c

c

c

MCI n (%)

0 (0)

30 (48.39)

138 (70.41)

52 (50.00)

 

c

c

c

c

*CN n (%)/*MCI n (%)

173 (100)/0 (0)

29 (46.77)/33 (53.23)

51 (26.02)/145 (73.98)

49 (47.12)/55 (52.88)

**χ2 = 17.18, (< 0.001)

c

c

c

c

sTREM2 mean (SD) [n]

3.71 (1.34) [173]

3.85 (1.17) [62]

5.06 (1.91) [196]

5.04 (1.69) [104]

F = 19.51, ηp2 = 0.10, (< 0.001)

bn.s. (n.s.)

b< 001 (< 001)

b < 001 (< 001)

bn.s. (n.s.)

YKL-40 mean (SD) [n]

143.26 (57.30) [154]

145.07 (49.49) [56]

210.93 (69.10) [167]

197.34 (58.49) [84]

F = 28.07, ηp2 = 0.16, (< 0.001)

bn.s. (n.s.)

b < 001 (< 001)

b < 001 (< 001)

bn.s. (n.s.)

Custerin mean (SD) [n]

1865.34 (582.52) [152]

1889.75 (630.50) [51]

2420.87 (752.67) [155]

2665.40 (872.20) [83]

F = 25.10, ηp2 = 0.15, (< 0.001)

bn.s. (n.s.)

b < 001 (< 001)

b < 001 (< 001)

b <0.05 (n.s.)

Fractalkine mean (SD) [n]

1848.57 (530.25) [146]

1810.54 (425.11) [46]

2256.21 (616.43) [137]

2379.51 (562.01) [80]

F = 21.23, ηp2 = 0.14, (< 0.001)

bn.s. (n.s.)

b < 001 (< 001)

b < 001 (< 001)

bn.s. (n.s.)

MCP-1 mean (SD) [n]

462.80 (109.86) [148]

476.01 (125.42) [54]

534.39 (152.82) [163]

516.18 (137.41) [80]

F = 2.63, ηp2 = 0.02, (< 0.05)

bn.s. (n.s.)

b < 05 (n.s.)

b < 05 (n.s.)

bn.s. (n.s.)

Il-6 mean (SD) [n]

1.66 (0.87) [147]

1.50 (0.62) [54]

1.57 (0.79) [162]

1.62 (0.74) [79]

F = 0.09, (0.996)

c

c

c

c

IL-10 mean (SD) [n]

78.83 (58.68) [92]

63.62 (27.73) [26]

80.87 (47.31) [89]

82.63 (55.58) [48]

F = 1.07, (0.363)

c

c

c

c

IL-18 mean (SD) [n]

5.76 (2.30) [147]

6.27 (4.72) [54]

6.61 (2.57) [167]

6.90 (2.69) [80]

F = 2.94 ηp2 = .02, (< 0.05)

bn.s. (n.s.)

b(n.s.) (n.s.)

b < 05 (n.s.)

bn.s. (n.s.)

IFN-γ mean (SD) [n]

51.73 (57.30) [92]

41.85 (40.76) [26]

57.54 (125.31) [90]

46.19 (20.91) [48]

F = 1.07, (0.363)

c

c

c

c

  1. A±, CSF positive or negative for amyloid plaques; T±, CSF positive or negative for tau-tangles; N±, CSF positive or negative marker for neurodegeneration; SD, standard deviation; n, number of cases; %, percentage; F, F statistic; χ2, chi square statistic; η2, eta-squared; ηp2, partial eta-squared; vs., versus; SCD, Subjective Cognitive Decline; CN, Cognitively Normal; MCI, Mild Cognitive Impairment. Significant statistical tests (ANOVA or ANCOVA, or between group comparisons after correction for multiple testing) are indicated in bold
  2. *Tally of CN and MCI according to our cognitive screening battery, regardless of recruitment as control or SCD status
  3. **Chi-square analyses do not include the CN A-/T-/N/-group
  4. aANOVA post-hoc (Bonferroni–Holm)
  5. bANCOVA comparisons (Bonferroni–Holm)
  6. cNo post-hoc comparisons performed
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094